Hallo ihr Kämpfer!

Bin von Vreni auf dieses Forum gestupst worden...
möchte mich kurz vorstellen, ich heißte Matthias, bin 27 Jahre alt (noch) und Assistenzarzt in der Chirurgie. Mein opa ist an BSDK gestorben.
Hatte Vreni versprochen, hier evntl. mal zu posten wenn ich fachlich helfen kann. z.b. kann ich was zu Xeloda sagen. Bei vielen Krebssorten ja ein gutes Mittel, leider mit der bekannten und von Vreni beschriebenen Nebenwirkung des Hand-Fuß-Syndroms.
Ich finde es richtig toll wie ihr hier euch gegenseitig Mut zusprecht und energie und Motivation freisetzt! Das ist genausogut wie jede sonstige Therapie!!! Beide Daumen hoch!!!

@Vreni: Habe mal zwei Artikel rausgekramt, die beantworten, warum bei Deiner Mami Xeloda auf 1-0-1 reduziert wurde. Leider sind sie in Englisch, aber das wesentliche hab ich mal drunter zusammengefasst ;-)



Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.

Scheithauer W, Blum J.

Department of Internal Medicine I, University of Vienna Medical School Vienna, Austria. Werner.Scheithauer@meduniwien.ac.at

Hand-foot syndrome is a localized cutaneous side effect associated with the administration of several chemotherapeutic agents, including the oralfluoropyrimidine capecitabine (Xeloda). It is never life-threatening but can develop into a painful and debilitating condition that interferes with patients' normal daily activities and quality of life. Several symptomatic/prophylactic treatments have been used to alleviate hand-foot syndrome, but as yet there is insufficient prospective clinical evidence to support their use. The only proven method of managing hand-foot syndrome is treatment modification (interruption and/or dose reduction), and this strategy is recommended for patients receiving capecitabine. Retrospective analysis of safety data from two large phase III trials investigating capecitabine as first-line therapy in patients with colorectal cancer confirms that this strategy is effective in the management of hand-foot syndrome and does not impair the efficacy of capecitabine. This finding is supported by studies evaluating capecitabine in metastatic breast cancer. Notably, the incidence and management of hand-foot syndrome are similar when capecitabine is administered in the metastatic and adjuvant settings, as monotherapy, or in combination with docetaxel (Taxotere). It is important that patients learn to recognize the symptoms of hand-foot syndrome, so that prompt symptomatic treatment and treatment modification strategies can be implemented.

PMID: 15471200 [PubMed - in process]





und:






Eur J Oncol Nurs. 2004;8 Suppl 1:S31-40. Related Articles, Links


Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).

Lassere Y, Hoff P.

Clinical Protocol Administration, MD Anderson Cancer Center, 1515 Holcombe Unit 426, Houston, TX 77030, USA. ylassere@mdanderson.org

Comparative trials of capecitabine (Xeloda) versus 5-FU/LV in metastatic colorectal cancer have shown that hand-foot syndrome (HFS) was the only clinical adverse event occurring more frequently with capecitabine. Most patients with HFS present with dysesthesia, usually with a tingling sensation in the palms and soles of the hands and feet. This can progress in 3-4 days to burning pain plus well-defined symmetric swelling and erythema. The hands tend to be more commonly affected than the feet, and might even be the only area affected in some patients. HFS can interfere with the general activities of daily living, especially when blistering, moist desquamation, severe pain or ulceration occurs. While HFS is manageable, if ignored it can progress rapidly. However, dose interruption and reduction of capecitabine usually leads to a rapid reversal of signs and symptoms without long-term consequences. Nurses play a key role in educating patients how to recognise HFS, when to interrupt treatment and how to adjust the dose to maintain effective therapy with capecitabine over the long term. It is particularly important that patients and nurses are aware that dose interruption/reduction does not affect the overall antitumour efficacy of capecitabine.

PMID: 15341880 [PubMed - in process]



Heißt auf deutsch, daß die Dosis nicht gewichtsabhängig eingestellt wird, sondern daß sich nach der Hauptnebenwirkung Hand-Fuß-Syndrom gerichtet wird, und, falls dieses Syndrom so stark wir bei Euch auftritt, die Dosis reduziert wird. Das ändert NICHTS an der Wirksamkeit der Chemotherapie.

kann leider nicht jeden Tag hier reinschauen, aber hoffe bissi geholfen zu haben/helfen zu können.

LG, Matthias